1. Home
  2. PEG vs INSM Comparison

PEG vs INSM Comparison

Compare PEG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Public Service Enterprise Group Incorporated

PEG

Public Service Enterprise Group Incorporated

HOLD

Current Price

$79.08

Market Cap

42.6B

Sector

Utilities

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$195.35

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEG
INSM
Founded
1903
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.6B
41.2B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
PEG
INSM
Price
$79.08
$195.35
Analyst Decision
Buy
Strong Buy
Analyst Count
13
19
Target Price
$92.25
$180.94
AVG Volume (30 Days)
2.7M
2.8M
Earning Date
11-03-2025
10-30-2025
Dividend Yield
3.19%
N/A
EPS Growth
2.23
N/A
EPS
4.16
N/A
Revenue
$11,718,000,000.00
$447,022,000.00
Revenue This Year
$19.75
$43.10
Revenue Next Year
$2.67
$128.25
P/E Ratio
$18.98
N/A
Revenue Growth
12.35
30.34
52 Week Low
$74.67
$60.40
52 Week High
$91.26
$212.75

Technical Indicators

Market Signals
Indicator
PEG
INSM
Relative Strength Index (RSI) 39.30 50.33
Support Level $77.90 $189.59
Resistance Level $80.52 $206.69
Average True Range (ATR) 1.28 6.43
MACD -0.32 -3.01
Stochastic Oscillator 20.10 23.53

Price Performance

Historical Comparison
PEG
INSM

About PEG Public Service Enterprise Group Incorporated

Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plans and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: